Project

Novel combination therapies to combat therapy resistant neuroblastoma: translating pre-clinical investigations to clinical trials

Code
365D1216
Duration
01 October 2016 → 31 December 2021
Funding
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other basic sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other clinical sciences
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other translational sciences
    • Other medical and health sciences
Keywords
neuroblastoma reduce toxicity chemotherapy
 
Project description

Neuroblastoma is an aggressive paediatric solid tumour originating from the sympathetic nervous system. New combination therapies are urgently warranted as high-risk neuroblastoma has a poor prognosis.
The aims of this project are two-fold: (1) further evaluate the efficacy and toxicity of nutlin, alectinib, palbociclib, silvestrol and TMPYP4 in combination with currently used chemotherapeutic agents in neuroblastoma treatment (2) to determine the therapeutic efficacy and toxicity of the individual compounds and most promising combinations of these compounds with currently used chemotherapeutics, in vivo using patient-derived tumour xenografts and neuroblastoma zebrafish models.
The ultimate goal is to offer compelling pre-clinical data and a framework to support and initiate the clinical evaluation of the most promising compounds in combination with conventional chemotherapy in patients with neuroblastoma to improve outcome and reduce toxicity.